New mRNA shingles vaccine shows promise in Mid-Stage trial
NCT ID NCT07285278
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new mRNA vaccine called ABO1108 to see if it can prevent shingles in adults aged 40 and above. About 300 healthy volunteers will receive two shots, two months apart, and be compared to a placebo group. The goal is to measure the immune response and check for safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABO1108 (mRNA vaccine for shingles)
- What this could lead to
- If successful, this could lead to a new, more effective shingles vaccine for adults 40 and older.
- What could go wrong
- This is an early Phase 2 trial with only 300 people, so results may not apply to everyone. The vaccine may not work as well as hoped or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VARICELLA-ZOSTER VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rongshui Miao Autonomous County Center for Disease Control and Prevention
Liuzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.